150 related articles for article (PubMed ID: 1967161)
1. Dopamine and dopamine receptor agonists in cardiovascular therapy.
Murphy MB; Elliott WJ
Crit Care Med; 1990 Jan; 18(1 Pt 2):S14-8. PubMed ID: 1967161
[TBL] [Abstract][Full Text] [Related]
2. The role of dopamine receptors in the treatment of congestive heart failure.
Goldberg LI
J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S19-27. PubMed ID: 2478806
[TBL] [Abstract][Full Text] [Related]
3. [New dopamine agonists in cardiovascular therapy].
Girbes AR; Van Veldhuisen DJ; Smit AJ
Presse Med; 1992 Aug 29-Sep 5; 21(27):1287-91. PubMed ID: 1359528
[TBL] [Abstract][Full Text] [Related]
4. Dopamine agonists, a new perspective in cardiovascular therapy?
Girbes AR; van Veldhuisen DJ; Smit AJ
Neth J Med; 1991 Aug; 39(1-2):65-71. PubMed ID: 1683693
[No Abstract] [Full Text] [Related]
5. Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.
Grenader A; Healy DP
J Pharmacol Exp Ther; 1991 Jul; 258(1):193-8. PubMed ID: 1677038
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
Zhao RR; Wang PH; Zhang WF; Fennell WH
Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
[TBL] [Abstract][Full Text] [Related]
7. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam.
Hedge SS; Ricci A; Amenta F; Lokhandwala MF
J Pharmacol Exp Ther; 1989 Dec; 251(3):1237-45. PubMed ID: 2574743
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam.
Christie MI; Smith GW
J Pharmacol Exp Ther; 1994 Feb; 268(2):565-70. PubMed ID: 7906731
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular responses in healthy subjects to a novel oral dopamine agonist, fenoldopam.
Cregeen RJ; Rudge PJ; Mills JG; Vincent SH; Burland WL
J Hypertens Suppl; 1985 Dec; 3(3):S173-5. PubMed ID: 2908814
[TBL] [Abstract][Full Text] [Related]
10. Role of dopamine receptors and the utility of dopamine agonists in heart failure.
Rajfer SI; Davis FR
Circulation; 1990 Aug; 82(2 Suppl):I97-102. PubMed ID: 1973645
[TBL] [Abstract][Full Text] [Related]
11. [New inotropic agents in the treatment of congestive heart failure].
Freitas M
Rev Port Cardiol; 1993 Nov; 12 Suppl 4():19-28, 7-8. PubMed ID: 7904458
[TBL] [Abstract][Full Text] [Related]
12. Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.
Aronson S; Goldberg LI; Roth S; Glock D; Moss J; Roizen MF
Can J Anaesth; 1990 Apr; 37(3):380-4. PubMed ID: 1969772
[TBL] [Abstract][Full Text] [Related]
13. Human vasodilator responses to a dopamine agonist: possible mechanisms.
Redman D; Thom SA; Hughes AD; Hasan S; Sever PS
J Hypertens Suppl; 1985 Dec; 3(3):S177-8. PubMed ID: 2908815
[TBL] [Abstract][Full Text] [Related]
14. Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
Casagrande C; Merlo L; La Regina A
J Auton Pharmacol; 1990; 10 Suppl 1():s85-93. PubMed ID: 1983011
[TBL] [Abstract][Full Text] [Related]
15. Dopamine and new dopamine analogs: receptors and clinical applications.
Goldberg LI
J Clin Anesth; 1988; 1(1):66-74. PubMed ID: 2908484
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Hasenfuss G; Just H
Basic Res Cardiol; 1989; 84 Suppl 1():191-6. PubMed ID: 2573341
[TBL] [Abstract][Full Text] [Related]
17. Dopamine and dopamine receptors as target sites for cardiovascular drug action.
Berkowitz BA
Fed Proc; 1983 Oct; 42(13):3019-21. PubMed ID: 6137421
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with intravenous fenoldopam.
Holcslaw TL; Beck TR
Am J Hypertens; 1990 Jun; 3(6 Pt 2):120S-125S. PubMed ID: 1974440
[TBL] [Abstract][Full Text] [Related]
19. The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure.
de Fijter CW; Comans EF; de Vries PM; Oe PL; Roos JC; Smit AJ; Streurman O; Donker AJ
Neth J Med; 1990 Jun; 36(5-6):267-78. PubMed ID: 1975651
[TBL] [Abstract][Full Text] [Related]
20. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
Alkadhi KA; Sabouni MH; Ansari AF; Lokhandwala MF
J Pharmacol Exp Ther; 1986 Aug; 238(2):547-53. PubMed ID: 2874213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
